MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Abbott

TCT 2010 roundup: Abbott keeps after Boston Scientific’s Taxus

By Leave a Comment

TCT2010, stent wars logo

Abbott (NYSE:ABT) kept up the pressure on Boston Scientific Corp. (NYSE:BSX) at a high-profile cardiology conference, releasing data from a pair of studies it says show that its Xience V drug-eluting stent is better than Boston Scientific’s competing Taxus.

Two-year data from the head-to-head trials of the paclitaxel-eluting Taxus against the everolimus-eluting Xience stent showed that more patients treated with BSX’s stent developed late-stent thrombosis. The data were presented in Washington, D.C., at the annual Transcatheter Cardiovascular Therapeutics conference.

Abbott’s XIENCE V Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial

By Leave a Comment

PRESS RELEASE

Late-breaking data were presented today from the investigator-initiated COMPARE trial of 1,800 real-world patients involving Abbott’s market-leading XIENCE V Everolimus Eluting Coronary Stent System and the TAXUS Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS). The results from COMPARE at two years were presented by Peter Smits, M.D., of Maasstad Ziekenhuis, Rotterdam, the Netherlands, during the Cardiovascular Research Foundation’s 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.

Abbott’s XIENCE V Shows Outstanding Two-Year Clinical Results Versus TAXUS in Key Safety and Efficacy Measures in SPIRIT IV Trial

By Leave a Comment

PRESS RELEASE

Late-breaking data from the SPIRIT IV trial, one of the largest randomized clinical trials between two drug eluting stents, continued to demonstrate outstanding clinical results of Abbott’s market-leading XIENCE V Everolimus Eluting Coronary Stent System versus the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System (TAXUS) in key areas of safety and efficacy through two years. The impressive two-year results were presented today by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center and NewYork-Presbyterian Hospital, during the Cardiovascular Research Foundation’s 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.

TCT 2010 roundup

By Leave a Comment

TCT2010, stent wars logo

A major battlefield in the stent wars opens again this week, as thousands of cardiologists and other healthcare providers flock to Washington, D.C., for the annual Transcatheter Cardiovascular Therapeutics conference.

Medical device industry players large and small are busy hawking the results of clinical trials and touting new products — or new versions of older products. TCT 2010, which kicked off yesterday, is slated to run through Sept. 25.

Abbott’s Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results

By Leave a Comment

PRESS RELEASE

Abbott today announced positive nine-month results from the first 45 patients enrolled in the second stage of the ABSORB trial. At nine months, Abbott’s bioresorbable vascular scaffold (BVS) demonstrated strong results that remained consistent with the six-month data from the same 45-patient group, with the rate of major adverse cardiac events (MACE) unchanged at 4.4 percent and no reports of blood clots (thromboses). These results were presented during the Cardiovascular Research Foundation’s 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.

Abbott continues double-digit sales growth during Q2

By Leave a Comment

ABT logo

Abbott (NYSE:ABT) posted flat second-quarter earnings despite a nearly 18 percent increase to its top line.

The Abbott Park, Ill.-based medical products conglomerate reported sales of $8.83 billion for the three months ended June 30, up 17.8 percent compared with $7.50 billion during the same period last year. But net earnings were flat at $1.29 billion, or 83 cents per diluted share, compared with the same numbers during Q2 2009.

FDA warns Abbott Diabetes Care on glucose strips

By Leave a Comment

ABT logo

The Food & Drug Administration warned Abbott’s (NYSE:ABT) diabetes care division after discovering problems at an Alameda, Calif., plant that makes glucose monitoring products.

In a July 2 letter, the federal watchdog said inspections revealed problems with the plant’s quality control and inspection processes. The plant makes Abbott’s FreeStyle glucose monitoring and Navigator continuous monitoring systems.

Abbott lays off 120 from California stents operation

By Leave a Comment

ABT logo

Abbott Laboratories (NYSE:ABT) laid off 120 workers from its California stent-making operation.

The Abbott Park, Ill.-based company laid off 101 workers from its Temecula and Murrieta vascular stent manufacturing facilities in the Golden State. The remaining 19 workers were let go from the company’s Santa Clara, Calif., location.

Abbott spokesman Jonathon Hamilton wrote in an emailed statement that the layoffs were “part of its regular business review process."

UPDATE: Stents war heats up at ACC conference

By Leave a Comment

The biggest names in the medical device world are busy touting the results of several clinical trials of their cardiovascular products, with more to come from the American College of Cardiology’s 59th annual scientific session.

Companies including Boston Scientific Corp. (NYSE:BSX), Johnson & Johnson (NYSE:JNJ), Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) are making presentation after presentation at the Atlanta conference, hoping to drum up abuzz among the attending surgeons.

Boston Scientific touts Taxus Express, Element data